Variables of timi risk score trial#

Last medically reviewed on March 21, 2018 Your healthcare provider should be able to explain your results in a way that you can easily understand. Talk to your doctor if you have any questions about your TIMI score.

keeping cholesterol and blood pressure levels in check.avoiding cigarette smoking and limiting alcohol consumption.You can lower your score, and your risk for a heart-related event, by: For example, if your TIMI score is on the high side, your physician might want to treat your condition more aggressively or pursue other kinds of medical intervention. Your score may help your physician come up with a treatment strategy. Knowing your risk for having a heart attack or other heart-related event can be extremely helpful to your healthcare provider. This means not every person will be given a TIMI score. All rights reserved.Doctors typically use the TIMI score on a select group of people with heart conditions that meet a certain criterion.

Variables of timi risk score trial#

(Improved Reduction of Outcomes: Vytorin Efficacy International Trial NCT00202878).Īcute coronary syndrome ezetimibe low-density lipoprotein cholesterol risk stratification secondary prevention simvastatin.Ĭopyright © 2017 American College of Cardiology Foundation. Similar findings were observed for the IMPROVE-IT primary CE.Ītherothrombotic risk stratification using the TRS 2°P identifies high-risk patients who derive greatest benefit from the addition of ezetimibe to statin therapy for secondary prevention after ACS. Low-risk patients (0 to 1 risk indicators n = 8,032 45%) did not appear to derive benefit from the addition of ezetimibe (p interaction = 0.010). Intermediate-risk patients (2 risk indicators n = 5,292 30%) had a 2.2% (95% confidence interval: -0.3% to 4.6%) absolute risk reduction. High-risk patients (n = 4,393 25%), defined by ≥3 risk indicators, had a 6.3% (95% confidence interval: 2.9% to 9.7%) absolute risk reduction in CV death/MI/iCVA at 7 years with ezetimibe/simvastatin, thus translating to a number-needed-to-treat of 16. The integer-based scheme showed a strong graded relationship with the rate of CV death/MI/iCVA, the trial CE, and the individual components (p trend <0.0001 for each). Treatment efficacy was assessed by baseline risk for CV death/MI/iCVA, the IMPROVE-IT composite endpoints (CE), and individual component endpoints at 7 years.Īll 9 clinical variables in the TRS 2°P were independent risk indicators for CV death/MI/iCVA (p < 0.001). The current study applied this tool prospectively to 17,717 post-ACS patients randomized either to ezetimibe and simvastatin or to placebo and simvastatin in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). The TIMI (Thrombolysis In Myocardial Infarction) Risk Score for Secondary Prevention (TRS 2°P) is a simple 9-point risk stratification tool, previously developed in a large population with atherothrombosis to predict CV death, myocardial infarction (MI), and ischemic stroke (CV death/MI/ischemic cerebrovascular accident ). This study tested the hypothesis that atherothrombotic risk stratification may be useful to identify post-ACS patients who have the greatest potential for benefit from the addition of ezetimibe to statin therapy. After ACS, patients vary considerably in their risk for recurrent CV events. Ezetimibe improves cardiovascular (CV) outcomes in patients stabilized after acute coronary syndrome (ACS) when added to statin therapy.